Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.0883 EUR -1.67% Market Closed
Market Cap: 16.8m EUR

Net Margin
Gensight Biologics SA

-7 793.8%
Current
-2 093%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-7 793.8%
=
Net Income
-15.1m
/
Revenue
194k

Net Margin Across Competitors

No Stocks Found

Gensight Biologics SA
Glance View

Market Cap
16.8m EUR
Industry
Biotechnology

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

SIGHT Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-7 793.8%
=
Net Income
-15.1m
/
Revenue
194k
What is the Net Margin of Gensight Biologics SA?

Based on Gensight Biologics SA's most recent financial statements, the company has Net Margin of -7 793.8%.

Back to Top